REPL Replimune Group Inc.

13.59
-0.91  -6%
Previous Close 14.5
Open 14.49
Price To Book 3
Market Cap 430080012
Shares 31,646,800
Volume 8,585
Short Ratio
Av. Daily Volume 106,929

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 ongoing. Phase 1 data to be presented 2H 2019 with Phase 2 part of trial to be initiated 1H 2019.
RP1 and nivolumab
Solid tumors
Phase 2 trial to be initiated 1H 2019.
RP1 and cemiplimab
Cutaneous squamous cell carcinoma (CSCC)